Berzosertib is a first-in-class small molecule inhibitor of the ataxia telangiectasia and Rad3-related protein (ATR), a critical regulator involved in DNA replication and cellular repair processes. Currently… Read more
Berzosertib is a first-in-class small molecule inhibitor of the ataxia telangiectasia and Rad3-related protein (ATR), a critical regulator involved in DNA replication and cellular repair processes. Currently under evaluation in various clinical trials, this investigational drug is being studied for its potential efficacy in treating a range of solid tumors, such as ovarian carcinoma and pancreatic cancer. To support pharmaceutical research and manufacturing, high-quality reference standards of Berzosertib, along with its associated impurities, metabolites, and stable isotope-labelled compounds, are required. These analytical materials are essential for conducting rigorous impurity profiling, structural elucidation, and quantitative analysis. Laboratories rely on these compounds to develop robust analytical methods, validate testing procedures, and ensure strict quality control during the development and characterization of this therapeutic agent.